Eloxx Pharmaceuticals
ELOX
20 hedge funds and large institutions have $41.3M invested in Eloxx Pharmaceuticals in 2026 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 5 closing their positions.
833% more capital inflows, than outflows
Capital inflows: $3.5M | Capital outflows: $375K
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
3.1% more ownership
Funds ownership: 63.8% → 66.9% (+3.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 22 → 20 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.11M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$309K |
| 3 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$47.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$21.5K |
| 5 |
Tower Research Capital (TRC)
New York
|
+$7.84K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stonepine Capital Management
Bend,
Oregon
|
-$235K |
| 2 |
Seven Grand Managers
Bronxville,
New York
|
-$139K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1K |
| 4 |
Barclays
London,
United Kingdom
|
-$167 |
| 5 |
Citigroup
New York
|
-$56 |
ELOX Hedge Fund Activity: Q3 2026 in Review
20 of the 8,114 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals (ELOX) for Q3 2026, worth a combined $41.3M — up 19% from $34.7M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ELOX and 3 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Morgan Stanley, adding an estimated $3.11M. The largest seller was Stonepine Capital Management, cutting an estimated $235K.
- 20 institutional investors held Eloxx Pharmaceuticals (ELOX) as of Q3 2026, down from 22 in Q2 2026.
- Funds reported $41.3M of Eloxx Pharmaceuticals stock for Q3 2026, up 19% quarter-over-quarter.
- 3 funds opened new Eloxx Pharmaceuticals positions in Q3 2026 and 5 closed out, a net change of -2 holders.
- The largest Eloxx Pharmaceuticals buyer in Q3 2026 was Morgan Stanley, an estimated $3.11M added.
- The largest Eloxx Pharmaceuticals seller in Q3 2026 was Stonepine Capital Management, an estimated $235K sold.
Based on aggregated 13F filings for Q3 2026.